Related Experiment Video
Updated: Sep 14, 2025

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
Exosome- transported FER inhibitor suppresses progression of diffuse large B-cell lymphoma via regulating AJUBA/Hippo
Jiarui Liu1, Yang Han1, Tiange Lu1
1Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, China.
Abstract:
FER, an intracellular tyrosine kinase, is ubiquitously expressed in malignancies. However, the regulatory mechanisms of FER in diffuse large B-cell lymphoma (DLBCL) remain elusive. Here, we found that FER was upregulated in DLBCL, leading to unfavorable outcomes and increased tumorigenesis, as well as resistance to chemotherapy. While exposing cells to the FER inhibitor E260, cell proliferation and tumor growth were repressed. Moreover, greater tumor suppression resulted from combining exosome-E260 with chemotherapeutics compared with the suppression achieved by monotherapy. Mechanistically, E260 restored the activity of Hippo signaling by inhibiting AJUBA, resulting in YAP cytoplasmic sequestration. Furthermore, circulating exosomal FER may act as an indicator for the diagnosis and progression of DLBCL. In summary, FER could serve as a prognostic indicator and therapeutic target in DLBCL. Additionally, the application of exosomes in diagnosis or treatment may open up novel avenues for cancer therapy.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Transcytosis of IgG
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
The Extrinsic Apoptotic Pathway
Regulation of Hematopoietic Stem Cells
PI3K/mTOR/AKT Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

